Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play
New York, January 21, 2026, 05:22 EST — Premarket Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase. (Public) Novavax’s deal is significant as the company looks to pivot its platform toward steadier revenue sources amid…